Clinical trial

HEME-25 Open-Label Feasibility Study of Elranatamab Utilized as Consolidation in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV

NCT07647432

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Elranatamab (Elra) Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

HEME-25 Open-Label Feasibility Study of Elranatamab Utilized as Consolidation in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV

Design: INTERVENTIONAL · Status: NOT YET RECRUITING · Phase: PHASE1

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2026-12-01

PhasePHASE1

Conditions

Plasmablastic Lymphomaverified · MONDO: plasmablastic lymphoma

HIVunresolved

Consolidationunresolved

Interventions

Elranatamab (Elra)DRUG

Sponsors & collaborators

University of Illinois at Chicagolead sponsor

Pfizercollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07647432 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.